OCGN
Ocugen, Inc.Company Information
- Company Name
- Ocugen, Inc.
- CIK
- CIK0001372299
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- OCGN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- OCGN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-15
- Last sale
- 2026-09-09
- Shares purchased (TTM)
- 21,000
- Shares sold (TTM)
- 468,727
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 144,119,774
- Shares outstanding
- 338,679,856
- Ownership
- 42.55%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 6.45%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Series B Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash | - | 32 | 19 | 33 | 27 | 38 | 59 | 39 | 16 | 26 | 39 | 53 | ||||||
| Cash And Cash Equivalents At Carrying Value | 100 | - | - | - | 27 | - | - | - | 16 | 26 | 39 | 53 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 7 | 6 | 5 | 6 | 6 | 3 | 2 | 3 | 4 | 4 | 3 | ||||||
| Assets Current | 107 | 39 | 24 | 38 | 33 | 44 | 62 | 41 | 19 | 30 | 43 | 57 | ||||||
| Property Plant And Equipment Net | 13 | 14 | 14 | 15 | 15 | 16 | 17 | 17 | 17 | 18 | 17 | 14 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Other Assets Noncurrent | 4 | 4 | 4 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Assets | 124 | 57 | 44 | 58 | 54 | 64 | 82 | 62 | 41 | 52 | 65 | 75 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 3 | 6 | 5 | 4 | 3 | 4 | 1 | 3 | 2 | 3 | 3 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | ||||||
| Derivative Liabilities Current | 34 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Long Term Debt Current | 0 | 5 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | ||||||
| Liabilities Current | 133 | 21 | 23 | 20 | 18 | 17 | 22 | 16 | 18 | 16 | 17 | 11 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 3 | 4 | 3 | ||||||
| Long Term Debt Noncurrent | 2 | 24 | 28 | 28 | 28 | 28 | 27 | 2 | 2 | 2 | 3 | 1 | ||||||
| Other Liabilities Noncurrent | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities Noncurrent | 8 | 30 | 33 | 34 | 33 | 32 | 31 | 6 | 6 | 5 | 7 | 5 | ||||||
| Liabilities | 141 | 51 | 56 | 54 | 51 | 49 | 53 | 21 | 24 | 22 | 24 | 16 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | - | 0 | - | ||||||
| Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Additional Paid In Capital | 432 | 430 | 393 | 391 | 370 | 369 | 367 | 364 | 328 | 326 | 324 | 322 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -452 | -427 | -408 | -390 | -370 | -356 | -340 | -326 | -313 | -298 | -286 | -267 | ||||||
| Stockholders Equity | -17 | 6 | -12 | 4 | 3 | 16 | 30 | 41 | 17 | 30 | 41 | 50 | ||||||
| Liabilities And Stockholders Equity | 124 | 57 | 44 | 58 | 54 | 64 | 82 | 62 | 41 | 52 | 65 | 75 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Outstanding | 0 | - | 0 | - | - | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Preferred Stock Shares Issued | 0 | - | 0 | - | - | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 390 | 390 | 390 | 390 | 390 | 390 | 390 | 390 | 295 | 295 | 390 | 295 | ||||||
| Common Stock Shares Issued | 339 | 338 | 313 | 312 | 292 | 292 | 291 | 290 | 258 | 257 | 257 | 257 | ||||||
| Shares Outstanding | 339 | 338 | 312 | 312 | 292 | 292 | 291 | 290 | 257 | 257 | 257 | 256 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOcugen, Inc. (OCGN) — SEC Financial Statements & Analysis
Ocugen, Inc. (OCGN) is a biological products, (no diagnostic substances) company, incorporated in DE. Ocugen, Inc. trades on Nasdaq as: OCGN. Ocugen, Inc. (OCGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Ocugen, Inc. carries a market cap of $518.18M, a P/E ratio of -6.33x, a P/B ratio of -31.30x, a P/S ratio of 113.14x, an enterprise value of $419.56M, and an EV/EBITDA multiple of -6.09x. On profitability, it posts an operating margin of -1504.43%, a net margin of -1786.27%, a Return on Equity (ROE) of 1211.66%, a Return on Assets (ROA) of -92.03%, and a Return on Invested Capital (ROIC) of -1562.64%. Per share, it reports EPS of $-0.24, diluted EPS of $-0.24, free cash flow per share of $-0.18, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -3.66% year-over-year, net income growth of 43.73% year-over-year, and EPS growth of 23.95% year-over-year. On the balance sheet, it maintains a current ratio of 0.80x, a quick ratio of 0.75x, working capital of $-26.36M, a debt-to-equity ratio of -8.50x, a debt ratio of 1.13, an interest coverage ratio of -8.16x, free cash flow of $-61.02M (TTM), and net debt of $-98.62M. Figures sourced from SEC EDGAR.
- Market Cap
- $518.18M
- P/E TTM
- -6.33x
- EPS TTM
- $-0.24
- P/B TTM
- -31.30x
- ROE TTM
- 1211.66%
- ROA TTM
- -92.03%
- Debt To Equity
- -8.50x
- Free Cash Flow TTM
- $-61.02M
- Net Revenue TTM Growth 1Y
- -3.66%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Ocugen, Inc. in?
Ocugen, Inc. (OCGN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does OCGN trade on?
Ocugen, Inc. (OCGN) trades on the Nasdaq.
Where is Ocugen, Inc. incorporated?
Ocugen, Inc. is incorporated in DE.
When was Ocugen, Inc. (OCGN)'s most recent SEC filing?
Ocugen, Inc. (OCGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is OCGN's market cap?
Ocugen, Inc. (OCGN) has a market capitalization of $518.18M as of 2026-06-30.
What is OCGN's EPS (earnings per share)?
Ocugen, Inc. (OCGN)'s trailing twelve month EPS is $-0.24 as of 2026-06-30.
What is OCGN's ROE (return on equity)?
Ocugen, Inc. (OCGN)'s trailing twelve month Return on Equity (ROE) is 1211.66% as of 2026-06-30.
What is OCGN's ROA (return on assets)?
Ocugen, Inc. (OCGN)'s trailing twelve month Return on Assets (ROA) is -92.03% as of 2026-06-30.
What is OCGN's ROIC (return on invested capital)?
Ocugen, Inc. (OCGN)'s trailing twelve month Return on Invested Capital (ROIC) is -1562.64% as of 2026-03-31.
What is OCGN's EV/EBITDA?
Ocugen, Inc. (OCGN)'s trailing twelve month EV/EBITDA is -6.09x as of 2026-06-30.